{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:59:29Z","timestamp":1792004369846,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40121-025-01294-0","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T08:10:33Z","timestamp":1767427833000},"page":"639-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Continuous Infusion of Aztreonam\u2013Avibactam After High Loading Dose for an Infection Caused by an OXA-48- and NDM-1-Co-producing ST147 Klebsiella pneumoniae"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5737-1484","authenticated-orcid":false,"given":"Paul","family":"Laffont-Lozes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7042-0160","authenticated-orcid":false,"given":"Fanny","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1598-6667","authenticated-orcid":false,"given":"C\u00e9line","family":"Mory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6463-9386","authenticated-orcid":false,"given":"Albert","family":"Sotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1218-9432","authenticated-orcid":false,"given":"Paul","family":"Loubet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2317-4199","authenticated-orcid":false,"given":"Alix","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-0901","authenticated-orcid":false,"given":"Romaric","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"1294_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect. 2022;28:521\u201347. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025.","journal-title":"Clin Microbiol Infect"},{"key":"1294_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","author":"PD Tamma","year":"2024","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae403.","journal-title":"Clin Infect Dis"},{"key":"1294_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jgar.2023.12.027","volume":"36","author":"GM Rossolini","year":"2024","unstructured":"Rossolini GM, Arhin FF, Kantecki M. In vitro activity of aztreonam-avibactam and comparators against metallo-\u03b2-lactamase-producing Enterobacterales from ATLAS Global Surveillance Program, 2016\u20132020. J Glob Antimicrob Resist. 2024;36:123\u201331. https:\/\/doi.org\/10.1016\/j.jgar.2023.12.027.","journal-title":"J Glob Antimicrob Resist"},{"key":"1294_CR4","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","volume":"72","author":"M Falcone","year":"2021","unstructured":"Falcone M, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase-producing enterobacterales. Clin Infect Dis. 2021;72:1871\u20138. https:\/\/doi.org\/10.1093\/cid\/ciaa586.","journal-title":"Clin Infect Dis"},{"key":"1294_CR5","unstructured":"Summary of product characteristics: Emblaveo. https:\/\/www.ema.europa.eu\/fr\/documents\/product-information\/emblaveo-epar-product-information_fr.pdf. Accessed 13 May\u00a02025."},{"key":"1294_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","volume":"25","author":"Y Carmeli","year":"2025","unstructured":"Carmeli Y, Cisneros JM, Paul M, et al. Aztreonam\u2013avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase\u00a03, randomised trial. Lancet Infect Dis. 2025;25:218\u201330. https:\/\/doi.org\/10.1016\/S1473-3099(24)00499-7.","journal-title":"Lancet Infect Dis"},{"key":"1294_CR7","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1093\/jac\/dkaa197","volume":"75","author":"TP Lodise","year":"2020","unstructured":"Lodise TP, Smith NM, O\u2019Donnell N, et al. Determining the optimal dosing of a novel combination regimen of ceftazidime\/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. J Antimicrob Chemother. 2020;75:2622\u201332. https:\/\/doi.org\/10.1093\/jac\/dkaa197.","journal-title":"J Antimicrob Chemother"},{"key":"1294_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cca.2017.03.009","volume":"468","author":"R Rigo-Bonnin","year":"2017","unstructured":"Rigo-Bonnin R, Ribera A, Arbiol-Roca A, et al. Development and validation of a measurement procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry for simultaneous measurement of \u03b2-lactam antibiotic concentration in human plasma. Clin Chim Acta. 2017;468:215\u201324. https:\/\/doi.org\/10.1016\/j.cca.2017.03.009.","journal-title":"Clin Chim Acta"},{"key":"1294_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02457-17","volume":"62","author":"K Avgoulea","year":"2018","unstructured":"Avgoulea K, Di Pilato V, Zarkotou O, et al. Characterization of extensively drug-resistant or pandrug-resistant sequence type\u00a0147 and 101 OXA-48-producing Klebsiella pneumoniae causing bloodstream infections in patients in an intensive care unit. Antimicrob Agents Chemother. 2018;62:e02457-17. https:\/\/doi.org\/10.1128\/AAC.02457-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1294_CR10","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s10096-022-04514-4","volume":"41","author":"LF Mataseje","year":"2022","unstructured":"Mataseje LF, Chen L, Peirano G, et al. Klebsiella pneumoniae ST147: and then there were three carbapenemases. Eur J Clin Microbiol Infect Dis. 2022;41:1467\u201372. https:\/\/doi.org\/10.1007\/s10096-022-04514-4.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1294_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","volume":"405","author":"N Macesic","year":"2025","unstructured":"Macesic N, Uhlemann A-C, Peleg AY. Multidrug-resistant Gram-negative bacterial infections. Lancet. 2025;405:257\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(24)02081-6.","journal-title":"Lancet"},{"key":"1294_CR12","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1093\/jac\/dkaf161","volume":"80","author":"HS Sader","year":"2025","unstructured":"Sader HS, Kimbrough JH, Winkler ML, Castanheira M, Mendes RE. Aztreonam\/avibactam activity against Enterobacterales from European medical centres: summary of 5\u00a0years of surveillance prior to approval for clinical use (2019\u20132023). J Antimicrob Chemother. 2025;80:2070\u20139. https:\/\/doi.org\/10.1093\/jac\/dkaf161.","journal-title":"J Antimicrob Chemother"},{"key":"1294_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107624","volume":"66","author":"ME Falagas","year":"2025","unstructured":"Falagas ME, Romanos LT, Kontogiannis DS, Filippou C. Resistance of Gram-negative bacteria to aztreonam-avibactam: an evaluation of data from in vitro studies. Int J Antimicrob Agents. 2025;66:107624. https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107624.","journal-title":"Int J Antimicrob Agents"},{"key":"1294_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01950-24","volume":"69","author":"R Xie","year":"2025","unstructured":"Xie R, Rogers H, Chow JW, Soto E, Raber SR, Leggett JE. Population pharmacokinetic\/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients. Antimicrob Agents Chemother. 2025;69:e01950-24. https:\/\/doi.org\/10.1128\/aac.01950-24.","journal-title":"Antimicrob Agents Chemother"},{"key":"1294_CR15","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1001\/jama.2024.9803","volume":"332","author":"MH Abdul-Aziz","year":"2024","unstructured":"Abdul-Aziz MH, Hammond NE, Brett SJ, et al. Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis. JAMA. 2024;332:638\u201348. https:\/\/doi.org\/10.1001\/jama.2024.9803.","journal-title":"JAMA"},{"key":"1294_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1224922","volume":"10","author":"Y Merad","year":"2023","unstructured":"Merad Y, Conrad A, Brosset S, et al. Case report: continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12\u00a0weeks for the treatment of bone and joint infections due to metallo-\u03b2-lactamase producing Enterobacterales. Front Med (Lausanne). 2023;10:1224922. https:\/\/doi.org\/10.3389\/fmed.2023.1224922.","journal-title":"Front Med (Lausanne)"},{"key":"1294_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00228-023-03609-x","volume":"80","author":"S Das","year":"2024","unstructured":"Das S, Riccobene T, Carrothers TJ, et al. Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for phase\u00a0IIa and phase\u00a0III evaluation. Eur J Clin Pharmacol. 2024;80:529\u201343. https:\/\/doi.org\/10.1007\/s00228-023-03609-x.","journal-title":"Eur J Clin Pharmacol"},{"key":"1294_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-023-00816-6","author":"L Baptista","year":"2023","unstructured":"Baptista L, Moura I, Silva CM, Baptista JP. What is new in augmented renal clearance in septic patients? Curr Infect Dis Rep. 2023. https:\/\/doi.org\/10.1007\/s11908-023-00816-6.","journal-title":"Curr Infect Dis Rep"},{"key":"1294_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081284","volume":"387","author":"J Braithwaite","year":"2024","unstructured":"Braithwaite J, Smith CL, Leask E, et al. Strategies and tactics to reduce the impact of healthcare on climate change: systematic review. BMJ. 2024;387:e081284. https:\/\/doi.org\/10.1136\/bmj-2024-081284.","journal-title":"BMJ"},{"key":"1294_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf421","author":"Y Fromage","year":"2025","unstructured":"Fromage Y, Sayadi H, Labriffe M, Monchaud C, Codde C, Woillard J-B. Reducing aztreonam\/avibactam waste: insights from Monte Carlo simulations. J Antimicrob Chemother. 2025. https:\/\/doi.org\/10.1093\/jac\/dkaf421.","journal-title":"J Antimicrob Chemother"},{"key":"1294_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jgar.2021.04.003","volume":"25","author":"C Rempenault","year":"2021","unstructured":"Rempenault C, Pagis V, Noussair L, et al. Treatment of bone and joint infections by ceftazidime\/avibactam and ceftolozane\/tazobactam: a cohort study. J Glob Antimicrob Resist. 2021;25:282\u20136. https:\/\/doi.org\/10.1016\/j.jgar.2021.04.003.","journal-title":"J Glob Antimicrob Resist"},{"key":"1294_CR22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","volume":"81","author":"AK Thabit","year":"2019","unstructured":"Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF. Antibiotic penetration into bone and joints: an updated review. Int J Infect Dis. 2019;81:128\u201336. https:\/\/doi.org\/10.1016\/j.ijid.2019.02.005.","journal-title":"Int J Infect Dis"},{"key":"1294_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/14787210.2025.2473047","volume":"23","author":"K Bush","year":"2025","unstructured":"Bush K. Past, present, and future perspectives on aztreonam and avibactam. Expert Rev Anti-Infect Ther. 2025;23:277\u201390. https:\/\/doi.org\/10.1080\/14787210.2025.2473047.","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"1294_CR24","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/phar.4629","volume":"44","author":"M Al Musawa","year":"2024","unstructured":"Al Musawa M, Bleick CR, Herbin SR, Caniff KE, Van Helden SR, Rybak MJ. Aztreonam\u2013avibactam: the dynamic duo against multidrug-resistant gram-negative pathogens. Pharmacotherapy. 2024;44:927\u201338. https:\/\/doi.org\/10.1002\/phar.4629.","journal-title":"Pharmacotherapy"},{"key":"1294_CR25","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/jac\/dkae058","volume":"79","author":"GM Assefa","year":"2024","unstructured":"Assefa GM, Roberts JA, Mohammed SA, Sime FB. What are the optimal pharmacokinetic\/pharmacodynamic targets for \u03b2-lactamase inhibitors? A systematic review. J Antimicrob Chemother. 2024;79:946\u201358. https:\/\/doi.org\/10.1093\/jac\/dkae058.","journal-title":"J Antimicrob Chemother"},{"key":"1294_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1001\/jamaoto.2014.2804","volume":"141","author":"LO Redaelli De Zinis","year":"2015","unstructured":"Redaelli De Zinis LO, Nassif N, Zanetti D. Long-term results and prognostic factors of underlay myringoplasty in pars tensa atelectasis in children. JAMA Otolaryngol Head Neck Surg. 2015;141:34. https:\/\/doi.org\/10.1001\/jamaoto.2014.2804.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"1294_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10162-025-00996-z","volume":"26","author":"N Hura","year":"2025","unstructured":"Hura N, Xia A, Santa Maria PL. Management strategies for chronic suppurative otitis media and why they fail. JARO. 2025;26:389\u201396. https:\/\/doi.org\/10.1007\/s10162-025-00996-z.","journal-title":"JARO"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01294-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01294-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01294-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:27:14Z","timestamp":1769678834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01294-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1294"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01294-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paul Laffont-Lozes has received support for attending meetings and\/or travel from Mundipharma. Albert Sotto has received consulting fees from Besins Healthcare and Karo Pharma, support for attending meetings and\/or travel from Pfizer and MSD and participates free of charge on advisory boards of Biofilm Control and CTX Laboratory. Paul Loubet has received personal consulting fees, payment or honoraria, and non-financial support for lectures, presentations, speakers\u2019 bureaus, or educational events from AstraZeneca, BioM\u00e9rieux, GSK, Gilead, Janssen, MSD, Moderna, Pfizer, Sanofi, ViiV Healthcare, Servier, Tillotts Pharma and Seqirus. Alix Pantel received speaker and consulting fees from bioM\u00e9rieux and Shionogi, and support for attending meetings and\/or travel from bioM\u00e9rieux, MSD, Shionogi and Pfizer. Romaric Larcher has received consulting fees from MSD, payment or honoraria for lectures, presentations, speakers\u2019 bureaus or educational events from bioM\u00e9rieux, MSD, Pfizer and Shionogi, and support for attending meetings and\/or travel from bioM\u00e9rieux, MSD, Pfizer and Shionogi. All other authors (Fanny Villa and C\u00e9line Mory) declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval was not required by the local ethics committee for this case report as it describes the patient\u2019s standard clinical management (continuous administration of \u03b2-lactam and TDM) in our institution. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. The patient provided written informed consent to participate in the study. The patient provided written informed consent for the publication of this report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}